

Attorney Docket No. 5405-311

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Newgard et al.

Serial No.: 10/573,207

International Application No.: PCT/US2004/031284

International Filing Date: September 23, 2004

International Priority Date: September 25, 2003

For: *RELATIONSHIP OF A SPECIFIC METABOLITE TO INSULIN RESISTANCE*

Date: July 27, 2006

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a Form PTO-1449 listing documents cited in the International Search Report for the corresponding International Application Number PCT/US2004/031284.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first substantive Office Action on the merits, whichever event occurs last.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. §1.56 and Section 609 of the MPEP. No fee is believed due; however, the Commissioner is hereby authorized to charge any deficiency or credit any refund to Deposit Account No. 50-0220.

Respectfully submitted,



Karen A. Magri
Registration No. 41,965


USPTO Customer No. 20792
Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401

CERTIFICATE OF EXPRESS MAIL

Express Mail Label Number: EV854925023US

Date of Deposit: July 27, 2006

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Katie Wu

Substitute form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/573,207	
			Filing Date	March 24, 2006	
			First Named Inventor	Newgard et al.	
			Group Art Unit	To be assigned	
			Examiner Name	To be assigned	
Sheet	A1	of	A1	Attorney Docket Number	5405-311

U.S. PATENTS AND PATENT PUBLICATIONS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1	International Search Report and the Written Opinion of the International Searching Authority for PCT Application No. PCT/US2004/031284 dated July 11, 2006.	
	2	An et al., "Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance," <i>Nature Medicine</i> , 10(3), March 2004, pp. 1-7..	
	3	Berciano et al., "Formation of Intracellular Crystalloids and Proliferation of the Smooth Endoplasmic Reticulum in Schwann Cells Induced by Tellurium Treatment: Association with Overexpression of HMG CoA Reductase and HMG CoA Synthase mRNA," <i>GLIA</i> , 29, 2000, pp. 246-259.	
	4	Fukao et al. "Succinyl-CoA:3-Ketoacid CoA Transferase (SCOT): Cloning of the Human SCOT Gene, Tertiary Structural Modeling of the Human SCOT Monomer, and Characterization of Three Pathogenic Mutations," <i>Genomics</i> , 68, 2000, pp. 144-151.	
	5	Mulder et al., "Overexpression of a modified human malonyl-CoA decarboxylase blocks the glucose-induced increase in malonyl-CoA level but has no impact on insulin secretion in INS-1-derived (832/13) β -cells," <i>The Journal of Biological Chemistry</i> , 276(9), March 2, 2001, pp. 6479-6484.	
	6	Nosadini et al., "Ketone body metabolism in normal and diabetic human skeletal muscle," <i>Am. J. Physiol.</i> , Vol. 249, 1985, pp. E131-136.	
	7	Oshida et al., "Effect of Insulin on Intramuscular 3-Hydroxybutyrate Levels in Diabetic Rats," <i>Horm. Metab. Res.</i> , 30, 1998, pp. 70-71.	
	8	Turko et al., "Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase," <i>Am. J. Physiol. Heart Circ. Physiol.</i> , 281, 2001, pp. H2289-H2294.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.